JNJ's Taubert to retire; Cavanaugh named EVP, Worldwide Chairman Innovative Medicine
Johnson & Johnson said Jennifer Taubert is stepping down after more than two decades at the company, with Tom Cavanaugh taking over effective September 1, 2026.
Johnson & Johnson disclosed in an August 4, 2026 8-K filing that Jennifer Taubert will step down as Executive Vice President, Worldwide Chairman, Innovative Medicine and leave the Executive Committee, with the change taking effect September 1, 2026.1
The company said Taubert is retiring after more than 21 years at Johnson & Johnson.1 Under her leadership, the company's Innovative Medicine business grew to more than $60 billion in annual revenue and became one of the most respected and successful pharmaceutical businesses in the world, according to the company.1
Taubert will be succeeded by Tom Cavanaugh, who currently serves as Company Group Chairman, North America, Innovative Medicine.1 The company said Cavanaugh has nearly three decades of experience in biopharmaceuticals spanning multiple therapeutic areas, functions, and geographies.1 He is set to join the Johnson & Johnson Executive Committee effective September 1, 2026.1
According to the filing, Cavanaugh joined Johnson & Johnson in 2017 and has held senior leadership roles in Oncology, Immunology and Global Commercial Strategy.1 Most recently, he led the company's largest commercial region, where he was said to have driven growth and strengthened execution.1 Before Johnson & Johnson, Cavanaugh spent nearly 15 years at Celgene in global product development, global medical affairs, marketing, and regional management roles in Spain and the U.S.1
CEO Joaquin Duato commented on both leaders in the release, and the company said the two will work together to ensure a smooth transition.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.